Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, March 14, 2018
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
Thursday, March 8, 2018
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
Tuesday, February 27, 2018
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Wednesday, February 21, 2018
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)
Friday, February 16, 2018
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Monday, February 12, 2018
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Thursday, February 1, 2018
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Monday, January 22, 2018
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Saturday, January 20, 2018
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: